Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease

Expert Opinion on Drug Safety

Volumn 16, Issue 3, 2017, Pages 303-317

  Mitrev, Nikola ^a   Leong, Rupert W ^a  

^a ANZAC Research Institute   (Australia)

Author keywords

Adalimumab; anti drug antibodies; anti tumour necrosis factor agents; certolizumab; Crohn s disease; golimumab; inflammatory bowel disease; infliximab; therapeutic drug monitoring; ulcerative colitis

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ANTIBODY PRODUCTION; CLINICAL DECISION MAKING; COST CONTROL; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFLAMMATORY BOWEL DISEASE; PHENOTYPE; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PATIENT SELECTION; PROCEDURES;

ANTIBODIES; DRUG MONITORING; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT SELECTION; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85013342257     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1269169     Document Type: Review

References (129)

1. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003 Feb 13;348(7):601–608.
2. Levin AD, Wildenberg ME, van den Brink GR., Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016 Aug;10(8):989–997.
3. Al-Taweel T, Strohl M, Kopylov U, et al. P529 Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn’s disease:the McGill experience. ECCO. 2016.
4. Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy:an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014 Jul;8(7):571–581.
5. Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis:a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015 May;9(5):693–700.
6. Ben-Horin S, Chowers Y., Review article:loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011 May;33(9):987–995.
7. Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs:definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
8. Sprakes MB, Ford AC, Warren L, et al. Tolerability, and predictors of response to infliximab therapy for Crohn’s disease:a large single centre experience. J Crohns Colitis. 2012 Mar;6(2):143–153.
9. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease:systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):644–659. quiz 60.
10. Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun;21(6):1435–1442.
11. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012 Aug 31;382(1–2):177–188.
12. Scott FI, Lichtenstein GR. Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2014 Mar;12(1):59–75.
13. Balsanek J, Willrich MAV, Murray DL, et al. Sa1268 clinical development of an electrochemiluminescent immunoassay to measure antibodies-to-infliximab. Gastroenterology. 2014;146(5):S1–S248.
14. Van Stappen T, Brouwers E, Vermeire S, et al. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2016 Mar 16. [Epub ahead of print].
15. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011 Oct 28;373(1–2):229–239.
16. Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016 Apr;22(8):1999–2015.
17. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013 Aug;35(4):530–538.
18. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease:post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014 Jul;109(7):1055–1064.• Comparison of four different assays demonstrated good correlation between anti-TNFα levels but poor correlation among antidrug antibody detection.
19. van Bezooijen JS, Koch BC, Doorn MV, et al. A comparison of three assays to quantify infliximab, adalimumab and etanercept serum concentrations. Ther Drug Monit. 2016 Aug;38(4):432–438.
20. Guiotto C, Daperno M, Frigerio F, et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Dig Liver Dis. 2016 Feb;48(2):138–143.
21. Malickova K, Duricova D, Bortlik M, et al. Serum trough infliximab levels:a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 2016 Jan;44(1):33–36.
22. Schmitz EM, van de Kerkhof D, Hamann D, et al. Therapeutic drug monitoring of infliximab:performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2016 Jul;54(7):1211–1219.
23. Steenholdt C, Brynskov J, Bendtzen K. Letter:persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD. Aliment Pharmacol Ther. 2012 Sep;36(5):499–500; author reply 01.
24. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals:assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007 Dec;46(12):1828–1834.
25. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn’s disease. J Crohns Colitis. 2015 Mar;9(3):238–245.
26. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30e2.•• Study used a ROC curve to define drug level and antidrug antibody titer cut offs that optimally predict for response to dose escalation, switching within class or switching out of class for patients with secondary loss of response to infliximab and adalimumab.
27. Ding NS, Hart A, De Cruz P. Systematic review:predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016 Jan;43(1):30–51.
28. Steenholdt C, Brynskov J, Thomsen, OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment:a randomised, controlled trial. Gut. 2014 Jun;63(6):919–927.• RCT demonstrating significant cost saving with a TDM-guided approach compared to empiric treatment for patients with loss of response to infliximab
29. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease:clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan;17(1):141–151.
30. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011 Feb;45(2):113–118.
31. Steenholdt C, Brynskov J, Thomsen, OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab. Dig Dis Sci. 2015 Sep;60(9):2762–2770.
32. Steenholdt C, Brynskov J, Thomsen OO, et al. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn’s disease. J Crohns Colitis. 2015 Nov;9(11):1032–1042.
33. Nguyen DL, Flores S, Sassi K, et al. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease. Ther Adv Chronic Dis. 2015 May;6(3):147–154.
34. Stein BN, Pellish RS, Thompson KD, et al. Using therapeutic drug monitoring to identify variable infliximab metabolism in an individual patient with ulcerative colitis. J Clin Gastroenterol. 2016 Jan;50(1):66–68.
35. Strik AS, Bots SJ, D’Haens G, et al. Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 2016 Mar;9(3):429–439.
36. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun;11(6):654–666.
37. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014 Oct;20(10):1708–1713.
38. Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn’s patients receiving maintenance adalimumab therapy:a post hoc analysis of the Karmiris trial. Gut. 2015 Apr;10(65):1126–1131.
39. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun;148(7):1320–1329 e3.•• The TAXIT study evaluated the benefits of proactive TDM, and although it did not reach its primary end point, it did demonstrate some benefits.
40. D’Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn’s disease:a prospective, randomised, multicentre trial (Tailorix). ECCO. 2016.
41. Amiot A, Hulin A, Belhassan M, et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90–98.
42. Armuzzi A, Felice C. IBD:Infliximab dose optimization in IBD-proactive or reactive? Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):706–708.
43. O’Toole A, Moss AC. Optimizing biologic agents in ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep. 2015 Aug;17(8):32.
44. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease:results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov;20(11):1996–2003.
45. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease:adding value to current practice. J Clin Pharmacol. 2015 Mar;55(Suppl 3):S39–S50.
46. Lefort A, Arthur M, Garry L, et al. Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo. Antimicrob Agents Chemother. 2000 Aug;44(8):2077–2080.
47. Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015 Jul;21(7):1709–1718.
48. Brandse JF, Mathot RA, van der Kleij D, et al. pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8 e1-e2.
49. Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm. 2014;2014:172821.
50. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease:a population pharmacokinetic study. Inflamm Bowel Dis. 2014 Dec;20(12):2247–2259.
51. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2013 Jul;29(4):391–396.
52. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease:pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr;91(4):635–646.
53. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008 Aug;30(4):523–529.
54. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660.
55. Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286–297.
56. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis. 2013 May;19(6):1112–1122.
57. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy:serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016 Apr;14(4):550–57e2.•• Cross-sectional study used ROC curve and concentration–effect curves to define therapeutic range for infliximab and adalimumab that optimally predicted mucosal healing
58. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):496–503.
59. Baumgart DC, Grittner U, Steingraber A, et al. phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy:experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011 Dec;17(12):2512–2520.
60. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy:results from the British Society for rheumatology biologics register. Ann Rheum Dis. 2009 Feb;68(2):209–215.
61. Cleynen I, Van Moerkercke W, Juergens M, et al. Anti-TNF induced cutaneous lesions in IBD patients:characterization and search for predisposing factors. Gut. 2010;59(S3):A1.
62. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec;147(6):1296–1307e5.
63. Bortlik M, Duricova D, Malickova K, et al.Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis. 2013 Oct;7(9):736–743.
64. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease:a prospective study. Inflamm Bowel Dis. 2013 Nov;19(12):2568–2576.
65. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol. 2011 Mar;46(3):310–318.
66. Moore C, Corbett G, Moss AC., Systematic review and meta-analysis:serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis. 2016 May;10(5):619–625.
67. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab:a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov;63(11):1721–1727.
68. Echarri A, Ferreiro R, Fraga-Iriso R, et al. Sa1264 Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease. Results of the optimiza study. Gastroenterology. 2014;146(5,Supplement 1):S–247.
69. Feagan BG, Singh S, Lockton S, et al. 565 Novel infliximab (IFX) and Antibody-to-Infliximab (ATI) assays are predictive of disease activity in patients with Crohn’s Disease (CD). Gastroenterology. 2012;142(5,Supplement 1):S–114.
70. Lamblin C, Aubourg A, Ternant D, et al. P334. Concentration–effect relationship of infliximab in Crohn’s disease:results of a cohort study. J Crohn’s Colitis 2012. 2012;6:S142–S143.
71. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease. Aliment Pharmacol Ther. 2014 May;39(10):1126–1135.
72. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248–1254.
73. Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016 Apr;14(4):543–549.
74. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab:a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010 Jan;59(1):49–54.
75. Vande Casteele N, Compernolle G, Ballet V, et al. Results on the optimisation phase of the prospective controlled Trough Level Adapted Infliximab Treatment (TAXIT) trial. Gastroenterology. 2012 May;142(5, S1):S211–S212.
76. Yarur A, Kanagala, V, Stein D, et al. 514 Higher infliximab trough levels are associated with a higher rate of perianal fistula healing in patients with Crohn’s disease. Gastroenterology. 2016;150(4,S1):S105–S106.
77. Ben-Bassat O, Romanova A, Iacono A, et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn’s disease. Gastroenterology. 2013;144(5):S775.
78. Drobne D, Bossuyt PJ, Breynaert C, et al. Crohn’s disease:infliximab trough levels and CRP during infliximab-immunomodulator combination treatment are associated with clinical outcome after immunomodulator withdrawal. Gastroenterology. 2011;140(5, Supplement 1):S–62.
79. Huang VW, Prosser C, Kroeker KI, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. Inflamm Bowel Dis. 2015 Jun;21(6):1359–1367.
80. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015 Oct;64(10):1539–1545.
81. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting:results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242–248.
82. Chaparro M, Barreiro-de Acosta M, Echarri A, et al. Correlation between anti-TNF serum levels and Mucosal Healing (MH) in Inflammatory Bowel Disease (IBD) patient. San Diego:Digestive Diseases Week; 2016.
83. Drobne D, Kurent T, Rajar P, et al. High infliximab trough levels are associated with better control of inflammation in IBD. San Diego:Digestive Diseases Week; 2016.
84. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance:a randomized trial. Gastroenterology. 2008 Jun;134(7):1861–1868.
85. Davidov, Y., Ungar, B., Bar-Yoseph, H., et al., Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease. J Crohns Colitis, 2016 Oct. E pub ahead of print.
86. Hibi, T., Sakuraba, A., Watanabeet, M., al., Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis, 2012. 18(8):p. 1480–1487.
87. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun;108(6):962–971.
88. Arias MT, Vande Casteele N, Drobne D, et al. OP10. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohns Colitis. 2012.Available from:http://dx.doi.org.ezproxy1.library.usyd.edu.au/10.1016/S1873-9946(12)60011-7 S5.
89. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10(10):1079–1087; quiz e85–e86.
90. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol. 2014 Jan;49(1):100–109.
91. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014 Sep;40(6):620–628.
92. Mostafa NM, Eckert D, Pradhan RS, et al. P333 Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis (UC). U Eur Gastroenterol J. 2013;1(S1):A221–A222.
93. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80–84e2.
94. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014 Aug;109(8):1250–1256.
95. Sharma S, Eckert D, Hyams, JS, et al.Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease:results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015 Apr;21(4):783–792.
96. Velayos FS, Sheibani S, Lockton S, et al. 490 Prevalence of Antibodies to Adalimumab (ATA) and correlation between ata and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology. 2013;144(5):S–91.
97. Yarur AJ, Deshpande AR, Sussman DA, et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology. 2013;144(5):S774–S775.
98. Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016 Feb;22(2):409–415.
99. Papamichael K, Baert F, Tops S, et al. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2016 Jul 11. Epub ahead of print.
100. Ward MG, Kariyawasam VC, Mogan SB, et al. Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2013;28(S2):82–111.
101. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease:current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr;16(4):378.
102. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109e1.
103. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Mar;12(3):423–431e1.
104. Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1103–1110.
105. Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–35e1.
106. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015 Aug;149(2):350–355e2.
107. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease:the ATLAS study. Gut. 2016 Feb;65(2):249–255.
108. Ungar, B., Mazor, Y., Weisshof, R., et al., Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther, 2016. 43(12):1293–1299.
109. Steenholdt C, Frederiksen MT, Bendtzen K, et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol. 2016 Jul;50(6):483–489.
110. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr 15;362(15):1383–1395.
111. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005 May;313(2):578–585.
112. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD):a meta-analysis. Am J Gastroenterol. 2013 Jan;108(1):40–47; quiz 48.
113. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases:a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jul;20(7):1288–1295.
114. Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease. Inflamm Bowel Dis. 2015 May;21(5):1176–1186.
115. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1474–14781e2; quiz e91.
116. Steenholdt C. Transient and persistent antibodies against TNF-inhibitors in IBD. Am J Gastroenterol. 2015 Nov;110(11):1623–1624.
117. Swoger JM, Levesque BG. Editorial:drug monitoring targets for optimising adalimumab in Crohn’s disease. Aliment Pharmacol Ther. 2014 Oct;40(7):854–855.
118. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Apr;11(4):444–447.
119. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009 Nov;137(5):1628–1640.
120. Minar P, Saeed SA, Afreen M, et al. Practical use of infliximab concentration monitoring in pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2016 May;62(5):715–722.
121. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol. 2009 Oct;104(10):2566–2571.
122. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008 Jun;103(6):1443–1450.
123. Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2016 Apr;22(4):912–918.
124. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133–1139.
125. Brandse JF, Strik AS, Mould D, et al. Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD. Gastroenterology. 2016;150(4, Supp 1):S144.
126. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan;142(1):63–70e5; quiz e31.
127. Ben-Horin S, Chowers Y, Ungar B, et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015 Aug;42(3):356–364.
128. Flamant M, Roblin X. Could therapeutic drug monitoring of anti-TNF-alpha be useful to consider a de-escalation of treatment? Expert Opin Biol Ther. 2015;15(11):1657–1660.
129. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012 Nov;18(11):2026–2033.